Leyden Laboratories
Develops antibody-based nasal sprays intended to prevent influenza and other respiratory-virus infections.
€40MSeries B
Role not disclosedC
ClavystBio
Activity from announced rounds
Activity in this selectionJun 30, 2026 · Jun 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $70.4M 2 disclosed · full round size, not this investor’s share